Navigation Links
A novel computational model -- how Parkinson's medications affect learning and attention

Newark, NJ A new brain-based computational model is helping to understand how Parkinson's disease and dopamine medicationsused to treat motor symptoms caused by the disease can affect learning and attention.

As reported in a forthcoming article in the Journal of Cognitive Neuroscience,, a new computational model, developed by Drs. Ahmed Moustafa and Mark Gluck, at the Center for Molecular and Behavioral Neuroscience at Rutgers University, Newark, has shown how Parkinson's disease affects attentional performance during learning.

The same model also shows that dopamine medications enhance attentional performance in Parkinson's patients in agreement with past observations. Future lab experiments with Parkinson's patients will be conducted by Moustafa and Mark Gluck to test further model predictions.

Parkinson's is a disease that mainly affects dopamine levels in a brain area known as the basal ganglia, which is important for motor control. Hence, damage to this area leads to movement disorders, including shaking and difficulty moving--key symptoms of Parkinson's disease.

Over the past two decades, it became known to neurologists and experimental neuroscientists that Parkinson's disease also affects non-motor functions, including memory, learning, and attention. Impairment in these processes affect the quality of life of the patients, thus, understanding the neural basis of motor and non-motor dysfunction in Parkinson's disease is equally important.

Dopamine is also projected to other parts of the brain, including the prefrontal cortex, an area important for higher-level thinking, decision making, and attention. Dopamine projected to the prefrontal cortex is also reduced in Parkinson's disease, as reported in many experimental studies with humans and animal models of Parkinson's disease.

According to Moustafa and Gluck, until recently, existing computational models of Parkinson's disease ignored any role played by dopamine in the prefrontal cortex. Moustafa and Gluck have designed a new computational model that shows how dopamine in the prefrontal cortex is important for attentional performance, and how dysfunction of dopamine in the prefrontal cortex can explain many of the non-motor deficits seen in Parkinson's patients.

"Computational models are increasingly being used in the neurosciences and neurology to understand how neurological disorders affect brain and behavior," said Moustafa. "This relatively new fieldknown as computational neuroscience is promising to aid in designing new pharmacological and surgical intervention tools to treat neurological and psychiatric diseases."


Contact: Helen Paxton
Rutgers University

Related medicine news :

1. TD2 and Critical Outcome Technologies Inc. develop novel anti-cancer drug
2. New human reproductive hormone could lead to novel contraceptives
3. Researchers discover novel method for detecting MIRCERA
4. Novel detection method unmasks circulating breast cancer cells
5. Turning metal black more than just a novelty
6. Engineers, doctors at UCLA develop novel material that could help fight arterial disease
7. Novel Technology in Treating Chronic Sinus Infections Available at Baptist
8. Novel K-anonymity algorithm safeguards access to data
9. Tulane Cancer Center to begin novel clinical trial for late-stage prostate cancer drug
10. Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain
11. Dallas Facial Plastic Surgeon Publishes Cutting-Edge Novel Approach To Facelift Technique
Post Your Comments:
(Date:11/25/2015)... , ... November 25, 2015 , ... ... has been recognized once again for its stellar workplace culture with the company’s ... , Medical Solutions’ Cincinnati office was named a finalist in Cincinnati ...
(Date:11/25/2015)... ... November 26, 2015 , ... ... European Union (EU), ANDI Pan African Centres of Excellence, and public R&D institutions, ... (UNON) for the opening of the 5th African Network for Drugs and Diagnostics ...
(Date:11/25/2015)... Angeles, CA (PRWEB) , ... November 25, 2015 , ... ... da Vinci surgical robot is being more and more widely heralded as a breakthrough ... assisted da Vinci method has over traditional laparoscopic surgery is that it can greatly ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug ... a new cutting edge recovery program that has been 50 years in the making. ... individuals with the purpose to free addicts from the symptoms and negative behaviors of ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 23rd 2015 Cozy ... personal heating products business. Cozy Products explains what this means for business moving ... well with the Cozy Products business model: to sell personal heaters that reduce energy ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... Nov. 25, 2015 AAIPharma Services Corp./Cambridge ... of at least $15.8  Million to expand its ... NC . The expansion will provide additional ... the growing demands of the pharmaceutical and biotechnology ... expansion will provide up to 40,000 square feet ...
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ), a ... start-up  biotechnology company focused on the development of ... by the F-Prime Biomedical Research Initiative (FBRI), today ... collaboration to support the discovery and development of ... Obsessive Compulsive disorders (OCD). ...
Breaking Medicine Technology: